IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by ROI Financial Advisors LLC

ROI Financial Advisors LLC reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,322 shares of the company’s stock after selling 675 shares during the quarter. IDEXX Laboratories accounts for 0.9% of ROI Financial Advisors LLC’s investment portfolio, making the stock its 27th largest position. ROI Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $1,373,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Prudential PLC boosted its position in IDEXX Laboratories by 3.6% in the 4th quarter. Prudential PLC now owns 52,672 shares of the company’s stock valued at $21,777,000 after buying an additional 1,835 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $23,067,000. Motley Fool Asset Management LLC lifted its stake in IDEXX Laboratories by 13.4% during the fourth quarter. Motley Fool Asset Management LLC now owns 4,456 shares of the company’s stock worth $1,842,000 after purchasing an additional 526 shares during the last quarter. Cynosure Group LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $1,831,000. Finally, Cinctive Capital Management LP raised its holdings in IDEXX Laboratories by 18.7% during the fourth quarter. Cinctive Capital Management LP now owns 3,942 shares of the company’s stock worth $1,630,000 after purchasing an additional 622 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $393.73 on Friday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a 50 day simple moving average of $435.55 and a 200-day simple moving average of $440.31. The company has a market cap of $31.91 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $393.50 and a 12-month high of $548.88.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on IDXX shares. Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday. Morgan Stanley lowered their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.